RT Journal Article
SR Electronic
T1 The Development and Validation of Radiopharmaceuticals Targeting Bacterial Infection
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 1676
OP 1682
DO 10.2967/jnumed.123.265906
VO 64
IS 11
A1 Alberto, Signore
A1 Ordonez, Alvaro A.
A1 Arjun, Chanda
A1 Aulakh, Gurpreet Kaur
A1 Beziere, Nicolas
A1 Dadachova, Ekaterina
A1 Ebenhan, Thomas
A1 Granados, Ulises
A1 Korde, Aruna
A1 Jalilian, Amirreza
A1 Lestari, Wening
A1 Mukherjee, Archana
A1 Petrik, Milos
A1 Sakr, Tamer
A1 Cuevas, Clara L. Santos
A1 Welling, Mick M.
A1 Zeevaart, Jan Rijn
A1 Jain, Sanjay K.
A1 Wilson, David M.
YR 2023
UL http://jnm.snmjournals.org/content/64/11/1676.abstract
AB The International Atomic Energy Agency organized a technical meeting at its headquarters in Vienna, Austria, in 2022 that included 17 experts representing 12 countries, whose research spanned the development and use of radiolabeled agents for imaging infection. The meeting focused largely on bacterial pathogens. The group discussed and evaluated the advantages and disadvantages of several radiopharmaceuticals, as well as the science driving various imaging approaches. The main objective was to understand why few infection-targeted radiotracers are used in clinical practice despite the urgent need to better characterize bacterial infections. This article summarizes the resulting consensus, at least among the included scientists and countries, on the current status of radiopharmaceutical development for infection imaging. Also included are opinions and recommendations regarding current research standards in this area. This and future International Atomic Energy Agency–sponsored collaborations will advance the goal of providing the medical community with innovative, practical tools for the specific image-based diagnosis of infection.